Skip to main content

Minodronate

  • Reference work entry
  • First Online:
Encyclopedia of Cancer
  • 175 Accesses

Synonyms

[1-hydroxy-2-(imidazo [1,2-a] pyridin-3-yl)ethylidene]-bisphosphonate; minodronic acid; Amino-bisphosphonate; Nitrogen-containing bisphosphonate; Third-generation bisphosphonate; Third-generation nitrogen-containing bisphosphonate; YM-529/ONO-5920; YM-529

Definition

Bisphosphonates are potent inhibitors of bone resorption and are widely used drugs for the treatment of osteoporosis, osteolytic bone metastasis, and tumor-associated hypercalcemia. These compounds have high affinity for calcium ions and therefore target bone mineral, where they are internalized by bone-resorbing osteoclasts and inhibit osteoclast function. Minodronate, a nitrogen-containing bisphosphonate, acts intracellularly by inhibiting farnesyl pyrophosphate synthase, thus leading to the inhibition of posttranslational prenylation of small molecular weight G proteins, which could also contribute to its anti-resorptive activity on osteoclasts and its antitumor effects in vivo.

Characteristics

Minodronate is...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 2,499.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Green JR, Clezardin P (2002) Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 25:S3–S9

    Article  PubMed  Google Scholar 

  2. Yamagishi S, Abe R, Inagaki Y et al (2004) Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol 165:1865–1874

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Yamagishi S, Matsui T, Nakamura K et al (2005) Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation. Int J Tissue React 27:189–195

    CAS  PubMed  Google Scholar 

  4. Yamagishi S, Nakamura K, Matsui T et al (2006) Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy. Med Hypotheses 66:273–275

    Article  CAS  PubMed  Google Scholar 

  5. Ylitalo R, Kalliovalkama J, Wu X et al (1998) Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. Pharmacol Toxicol 83:125–131

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sho-ichi Yamagishi .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this entry

Cite this entry

Yamagishi, Si. (2011). Minodronate. In: Schwab, M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-16483-5_3757

Download citation

Publish with us

Policies and ethics